- Home
- SLRN
SLRN
ACELYRIN INC.
as 12-20-2024 3:42pm EST
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | AGOURA HILLS |
| Market Cap: | 485.6M | IPO Year: | 2023 |
| Target Price: | $11.75 | AVG Volume (30 days): | 811.9K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.10 - $8.89 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ACELYRIN INC. News
SLRN Breaking Stock News: Dive into SLRN Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Simply Wall St.
23 days ago
Promising US Penny Stocks To Consider In November 2024
GuruFocus.com
a month ago
Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ...
GlobeNewswire
a month ago
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
a month ago
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
GlobeNewswire
2 months ago
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
GlobeNewswire
3 months ago
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
GuruFocus.com
3 months ago
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc
Compare SLRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLRN ACELYRIN INC. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.